Cullinan Therapeutics, Inc. 8-K — AI Bull & Bear Analysis

The latest 8-K filing from Cullinan Therapeutics presents a classic biotech trade-off between high-reward clinical signals and significant safety and financial risks. While the B-cell depletion data is promising, the company's admission that it is still evaluating target doses and the presence of serious adverse events highlight the volatility of the asset. Investors are now weighing the potential for a breakthrough in refractory autoimmune treatment against the reality of a cash-burning clinical-stage company with a fragile safety profile.